Abstract
IL-16 is a ligand and chemotactic factor for CD4+ T cells. IL-16 inhibits the CD3 mediated lymphocyte activation and proliferation. The effects of IL-16 on the target cells are dependent on the cell type, the presence of co-activators etc. To understand the regulation function and mechanism of IL-16 on target cells, we used a 130 a.a. recombinant IL-16 to study its effects on the growth of Jurkat T leukemia cells in vitro. We found that the rIL-16 stimulated the proliferation of Jurkat cells at low dose (10(-9)M), but inhibited the growth of the cells at higher concentration (10(-5)M). Results showed that 10(-5) M of rIL-16 treatment induced an enhanced apoptosis in Jurkat cells. The treatment blocked the expression of FasL, but up-regulated the c-myc and Bid expression in the cells. Pre-treatment of PKC inhibitor or MEK1 inhibitor markedly increased or decreased the rIL-16 induced growth-inhibiting effects on Jurkat cells, respectively. The results suggested that the rIL-16 might be a regulator for the growth or apoptosis of Jurkat cells at a dose-dependent manner. The growth-inhibiting effects of rIL-16 might be Fas/FasL independent, but, associated with the activation of PKC, up-regulated expression of c-Myc and Bid, and the participation of the ERK signal pathway in Jurkat cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / drug effects
-
Apoptosis / genetics
-
Apoptosis / immunology
-
BH3 Interacting Domain Death Agonist Protein
-
CD4 Antigens / immunology*
-
CD4 Antigens / metabolism
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology*
-
CD4-Positive T-Lymphocytes / metabolism
-
Carrier Proteins / drug effects
-
Carrier Proteins / genetics
-
Carrier Proteins / immunology
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / immunology
-
Cell Division / drug effects
-
Cell Division / genetics
-
Cell Division / immunology*
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / pharmacology
-
Fas Ligand Protein
-
Humans
-
Interleukin-16 / genetics
-
Interleukin-16 / immunology*
-
Interleukin-16 / pharmacology
-
Jurkat Cells
-
Leukemia, T-Cell / drug therapy
-
Leukemia, T-Cell / immunology*
-
Leukemia, T-Cell / metabolism
-
MAP Kinase Signaling System / drug effects
-
MAP Kinase Signaling System / genetics
-
MAP Kinase Signaling System / immunology
-
Membrane Glycoproteins / drug effects
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / immunology
-
Protein Kinase C / drug effects
-
Protein Kinase C / genetics
-
Protein Kinase C / immunology
-
Proto-Oncogene Proteins c-myc / drug effects
-
Proto-Oncogene Proteins c-myc / genetics
-
Proto-Oncogene Proteins c-myc / immunology
-
Recombinant Fusion Proteins / pharmacology
-
Signal Transduction / drug effects
-
Signal Transduction / genetics
-
Signal Transduction / immunology*
Substances
-
BH3 Interacting Domain Death Agonist Protein
-
BID protein, human
-
CD4 Antigens
-
Carrier Proteins
-
Cell Cycle Proteins
-
Enzyme Inhibitors
-
FASLG protein, human
-
Fas Ligand Protein
-
Interleukin-16
-
Membrane Glycoproteins
-
Proto-Oncogene Proteins c-myc
-
Recombinant Fusion Proteins
-
Protein Kinase C